OMG and myeloid sarcoma: Regarding final diagnoses, 33.3% of patients were diagnosed with multiple sclerosis (MS), 36.6% with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), 6.6% with neuromyelitis optica (NMO), 10% with acute disseminated encephalomyelitis (ADEM), and 13.3% with other demyelinating disorders.